Skip to main navigation Skip to search Skip to main content

Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer

  • Nasser Altorki
  • , Xiaofei Wang
  • , David Kozono
  • , Colleen Watt
  • , Rodney Landrenau
  • , Dennis Wigle
  • , Jeffrey Port
  • , David R. Jones
  • , Massimo Conti
  • , Ahmad S. Ashrafi
  • , Moishe Liberman
  • , Kazuhiro Yasufuku
  • , Stephen Yang
  • , John D. Mitchell
  • , Harvey Pass
  • , Robert Keenan
  • , Thomas Bauer
  • , Daniel Miller
  • , Leslie J. Kohman
  • , Thomas E. Stinchcombe
  • Everett Vokes
  • New York Presbyterian Hospital
  • Duke University
  • Alliance Protocol Operations Office
  • University of Pittsburgh
  • Mayo Clinic Rochester, MN
  • Memorial Sloan-Kettering Cancer Center
  • Institut Universitaire de Cardiologie et Pneumologie de Québec
  • Surrey Memorial Hospital
  • Centre Hospitalier de L'Universite de Montreal
  • University of Toronto
  • Johns Hopkins University
  • University of Colorado Health
  • New York University
  • Moffitt Cancer Center
  • Emory University
  • SUNY Upstate Medical University
  • The University of Chicago

Research output: Contribution to journal › Article › peer-review

1205 Scopus citations

Abstract

Background: The increased detection of small-sized peripheral non-small-cell lung cancer (NSCLC) has renewed interest in sublobar resection in lieu of lobectomy. Methods: We conducted a multicenter, noninferiority, phase 3 trial in which patients with NSCLC clinically staged as T1aN0 (tumor size, ≤2 cm) were randomly assigned to undergo sublobar resection or lobar resection after intraoperative confirmation of node-negative disease. The primary end point was disease-free survival, defined as the time between randomization and disease recurrence or death from any cause. Secondary end points were overall survival, locoregional and systemic recurrence, and pulmonary functions. Results: From June 2007 through March 2017, a total of 697 patients were assigned to undergo sublobar resection (340 patients) or lobar resection (357 patients). After a median follow-up of 7 years, sublobar resection was noninferior to lobar resection for disease-free survival (hazard ratio for disease recurrence or death, 1.01; 90% confidence interval [CI], 0.83 to 1.24). In addition, overall survival after sublobar resection was similar to that after lobar resection (hazard ratio for death, 0.95; 95% CI, 0.72 to 1.26). The 5-year disease-free survival was 63.6% (95% CI, 57.9 to 68.8) after sublobar resection and 64.1% (95% CI, 58.5 to 69.0) after lobar resection. The 5-year overall survival was 80.3% (95% CI, 75.5 to 84.3) after sublobar resection and 78.9% (95% CI, 74.1 to 82.9) after lobar resection. No substantial difference was seen between the two groups in the incidence of locoregional or distant recurrence. At 6 months postoperatively, a between-group difference of 2 percentage points was measured in the median percentage of predicted forced expiratory volume in 1 second, favoring the sublobar-resection group. Conclusions: In patients with peripheral NSCLC with a tumor size of 2 cm or less and pathologically confirmed node-negative disease in the hilar and mediastinal lymph nodes, sublobar resection was not inferior to lobectomy with respect to disease-free survival. Overall survival was similar with the two procedures.

Original languageEnglish
Pages (from-to)489-498
Number of pages10
JournalNew England Journal of Medicine
Volume388
Issue number6
DOIs
StatePublished - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Hematology/Oncology
  • Lung Cancer
  • Pulmonary/Critical Care
  • Pulmonary/Critical Care General
  • Surgery
  • Surgery General
  • Treatments in Oncology

Fingerprint

Dive into the research topics of 'Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this